This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.

How to buy Athersys stock | $1.77

Own Athersys stock in just a few minutes.

Posted

Fact checked

Athersys, Inc is a biotechnology business based in the US. Athersys shares (ATHX) are listed on the NASDAQ and all prices are listed in US Dollars. Athersys employs 83 staff and has a trailing 12-month revenue of around USD$10,000.

How to buy shares in Athersys

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Athersys. Find the stock by name or ticker symbol: ATHX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Athersys reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$1.77, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Athersys, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Athersys. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Athersys share price

Use our graph to track the performance of ATHX stocks over time.

Athersys shares at a glance

Information last updated 2020-10-19.
Latest market close USD$1.77
52-week range USD$1.13 - USD$4.38
50-day moving average USD$2.0053
200-day moving average USD$2.5288
Wall St. target price USD$7.4
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.306

Buy Athersys shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Athersys stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Athersys price performance over time

Historical closes compared with the close of $1.77 from 2020-11-16

1 week (2020-11-25) 1.77
1 month (2020-11-06) 0.57%
3 months (2020-09-04) -10.15%
6 months (2020-06-05) -36.33%
1 year (2019-12-05) 36.15%
2 years (2018-12-04) -5.35%
3 years (2017-12-05) -4.32%
5 years (2015-12-04) 60.91%

Athersys financials

Revenue TTM USD$10,000
Gross profit TTM USD$-33,412,000
Return on assets TTM -50.49%
Return on equity TTM -114.86%
Profit margin 0%
Book value $0.326
Market capitalisation USD$353.4 million

TTM: trailing 12 months

Shorting Athersys shares

There are currently 24.2 million Athersys shares held short by investors – that's known as Athersys's "short interest". This figure is 1.9% up from 23.7 million last month.

There are a few different ways that this level of interest in shorting Athersys shares can be evaluated.

Athersys's "short interest ratio" (SIR)

Athersys's "short interest ratio" (SIR) is the quantity of Athersys shares currently shorted divided by the average quantity of Athersys shares traded daily (recently around 2.0 million). Athersys's SIR currently stands at 12.37. In other words for every 100,000 Athersys shares traded daily on the market, roughly 12370 shares are currently held short.

However Athersys's short interest can also be evaluated against the total number of Athersys shares, or, against the total number of tradable Athersys shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Athersys's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 Athersys shares in existence, roughly 120 shares are currently held short) or 0.1358% of the tradable shares (for every 100,000 tradable Athersys shares, roughly 136 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Athersys.

Find out more about how you can short Athersys stock.

Athersys share dividends

We're not expecting Athersys to pay a dividend over the next 12 months.

Have Athersys's shares ever split?

Athersys's shares were split on 5 June 2007. This wouldn't directly have changed the overall worth of your Athersys shares – just the quantity. However, indirectly, the new INF% higher share price could have impacted the market appetite for Athersys shares which in turn could have impacted Athersys's share price.

Athersys share price volatility

Over the last 12 months, Athersys's shares have ranged in value from as little as $1.13 up to $4.38. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Athersys's is -1.7463. This would suggest that Athersys's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Athersys has bucked the trend.

Athersys overview

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as in Phase II clinical study for the treatment of patients with acute myocardial infarction, and has completed Phase I clinical study for the treatment of patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site